298 related articles for article (PubMed ID: 21386934)
1. Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.
Munger MA
P T; 2011 Jan; 36(1):22-40. PubMed ID: 21386934
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
3. The place of ARBs in heart failure therapy: is aldosterone suppression the key?
Markan U; Pasupuleti S; Pollard CM; Perez A; Aukszi B; Lymperopoulos A
Ther Adv Cardiovasc Dis; 2019; 13():1753944719868134. PubMed ID: 31401939
[TBL] [Abstract][Full Text] [Related]
4. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Werner C; Pöss J; Böhm M
Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
[TBL] [Abstract][Full Text] [Related]
5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
6. A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications.
Zaiken K; Hudd TR; Cheng JW
Ann Pharmacother; 2013 May; 47(5):686-93. PubMed ID: 23585649
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.
Al Khalaf MM; Thalib L; Doi SA
Am J Cardiovasc Drugs; 2009; 9(1):29-43. PubMed ID: 19178130
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension.
Akioyamen L; Levine M; Sherifali D; O'Reilly D; Frankfurter C; Pullenayegum E; Goeree R; Tsoi B
J Am Soc Hypertens; 2016 Jan; 10(1):55-69.e1. PubMed ID: 26684588
[TBL] [Abstract][Full Text] [Related]
9. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.
Wang X; Ye Y; Gong H; Wu J; Yuan J; Wang S; Yin P; Ding Z; Kang L; Jiang Q; Zhang W; Li Y; Ge J; Zou Y
J Mol Cell Cardiol; 2016 Aug; 97():180-90. PubMed ID: 27210827
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
[TBL] [Abstract][Full Text] [Related]
12. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Nixon RM; Müller E; Lowy A; Falvey H
Int J Clin Pract; 2009 May; 63(5):766-75. PubMed ID: 19392925
[TBL] [Abstract][Full Text] [Related]
13. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
14. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
Dzau V
J Hypertens Suppl; 2005 Apr; 23(1):S9-17. PubMed ID: 15821452
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro.
Zakrocka I; Targowska-Duda KM; Wnorowski A; Kocki T; Jóźwiak K; Turski WA
Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):209-217. PubMed ID: 30370429
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults.
Dorosch T; Ganzer CA; Lin M; Seifan A
Curr Pain Headache Rep; 2019 Sep; 23(11):85. PubMed ID: 31515634
[TBL] [Abstract][Full Text] [Related]
17. Comparative assessment of angiotensin receptor blockers in different clinical settings.
Verdecchia P; Angeli F; Repaci S; Mazzotta G; Gentile G; Reboldi G
Vasc Health Risk Manag; 2009; 5():939-48. PubMed ID: 19997575
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
19. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Stumpe KO
Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]